Nabriva Therapeutics AG (NASDAQ:NBRV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday. The brokerage currently has a $12.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s target price suggests a potential upside of 20.00% from the stock’s current price.
According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “
Several other research firms also recently weighed in on NBRV. Cantor Fitzgerald restated an “overweight” rating on shares of Nabriva Therapeutics AG in a report on Friday, June 23rd. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Nabriva Therapeutics AG in a research note on Friday, June 30th. ValuEngine upgraded Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. Finally, Wedbush reiterated an “outperform” rating and issued a $13.00 target price on shares of Nabriva Therapeutics AG in a research note on Monday, May 15th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $15.43.
Shares of Nabriva Therapeutics AG (NASDAQ NBRV) opened at 10.00 on Thursday. The company has a 50-day moving average of $10.40 and a 200 day moving average of $10.35. The company’s market capitalization is $268.38 million. Nabriva Therapeutics AG has a 52-week low of $3.52 and a 52-week high of $12.75.
Nabriva Therapeutics AG (NASDAQ:NBRV) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($5.83) by $5.29. The business had revenue of $1.05 million for the quarter, compared to the consensus estimate of $1.34 million. Analysts predict that Nabriva Therapeutics AG will post ($2.43) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by BBNS and is owned by of BBNS. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/nabriva-therapeutics-ag-nbrv-stock-rating-upgraded-by-zacks-investment-research/1441547.html.
In other news, Director George Harrison Talbot sold 325 shares of the business’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $100.56, for a total transaction of $32,682.00. Following the sale, the director now owns 3,854 shares in the company, valued at $387,558.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Hbm Healthcare Investments (Ca sold 8,558 shares of the business’s stock in a transaction dated Thursday, June 29th. The stock was sold at an average price of $10.96, for a total value of $93,795.68. Following the sale, the insider now owns 2,591,396 shares in the company, valued at approximately $28,401,700.16. The disclosure for this sale can be found here. Insiders sold 242,708 shares of company stock worth $2,646,784 in the last quarter.
Several large investors have recently modified their holdings of NBRV. Wellington Management Group LLP raised its stake in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares during the last quarter. Almanack Investment Partners LLC. raised its stake in shares of Nabriva Therapeutics AG by 482.2% in the second quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock worth $1,633,000 after buying an additional 751,366 shares during the last quarter. Nationwide Fund Advisors raised its stake in shares of Nabriva Therapeutics AG by 4.6% in the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock worth $2,032,000 after buying an additional 7,924 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Nabriva Therapeutics AG during the fourth quarter worth $103,000. Institutional investors and hedge funds own 56.65% of the company’s stock.
About Nabriva Therapeutics AG
Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with our FREE daily email newsletter.